CORD-19:775b90287b44353bee979abb0970a4666022f86d / 767594-767863 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"T97046","span":{"begin":0,"end":269},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Treatment-related adverse events occurring in ≥ 1% subjects included blurred vision (4.5% vs 4.1%), abnormal sensation in eye (2.1% vs 4.1%), dry eye (2.4% vs 3%), eye irritation (0.3% vs 3%), and dysgeusia (2.4% vs 0%), in olopatadine and vehicle groups, respectively."}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T333","span":{"begin":0,"end":269},"obj":"Sentence"}],"text":"Treatment-related adverse events occurring in ≥ 1% subjects included blurred vision (4.5% vs 4.1%), abnormal sensation in eye (2.1% vs 4.1%), dry eye (2.4% vs 3%), eye irritation (0.3% vs 3%), and dysgeusia (2.4% vs 0%), in olopatadine and vehicle groups, respectively."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T5774","span":{"begin":142,"end":149},"obj":"Disease"},{"id":"T46209","span":{"begin":142,"end":149},"obj":"Disease"}],"attributes":[{"id":"A5774","pred":"mondo_id","subj":"T5774","obj":"http://purl.obolibrary.org/obo/MONDO_0006733"},{"id":"A13388","pred":"mondo_id","subj":"T46209","obj":"http://purl.obolibrary.org/obo/MONDO_0006733"}],"text":"Treatment-related adverse events occurring in ≥ 1% subjects included blurred vision (4.5% vs 4.1%), abnormal sensation in eye (2.1% vs 4.1%), dry eye (2.4% vs 3%), eye irritation (0.3% vs 3%), and dysgeusia (2.4% vs 0%), in olopatadine and vehicle groups, respectively."}

{"project":"CORD-19-PD-HP","denotations":[{"id":"T4032","span":{"begin":69,"end":83},"obj":"Phenotype"},{"id":"T4033","span":{"begin":197,"end":206},"obj":"Phenotype"}],"attributes":[{"id":"A4032","pred":"hp_id","subj":"T4032","obj":"http://purl.obolibrary.org/obo/HP_0000622"},{"id":"A4033","pred":"hp_id","subj":"T4033","obj":"http://purl.obolibrary.org/obo/HP_0031249"}],"text":"Treatment-related adverse events occurring in ≥ 1% subjects included blurred vision (4.5% vs 4.1%), abnormal sensation in eye (2.1% vs 4.1%), dry eye (2.4% vs 3%), eye irritation (0.3% vs 3%), and dysgeusia (2.4% vs 0%), in olopatadine and vehicle groups, respectively."}

{"project":"CORD-19-PD-UBERON","denotations":[{"id":"T1525","span":{"begin":122,"end":125},"obj":"Body_part"},{"id":"T1526","span":{"begin":146,"end":149},"obj":"Body_part"},{"id":"T1527","span":{"begin":164,"end":167},"obj":"Body_part"}],"attributes":[{"id":"A1525","pred":"uberon_id","subj":"T1525","obj":"http://purl.obolibrary.org/obo/UBERON_0000970"},{"id":"A1526","pred":"uberon_id","subj":"T1526","obj":"http://purl.obolibrary.org/obo/UBERON_0000970"},{"id":"A1527","pred":"uberon_id","subj":"T1527","obj":"http://purl.obolibrary.org/obo/UBERON_0000970"}],"text":"Treatment-related adverse events occurring in ≥ 1% subjects included blurred vision (4.5% vs 4.1%), abnormal sensation in eye (2.1% vs 4.1%), dry eye (2.4% vs 3%), eye irritation (0.3% vs 3%), and dysgeusia (2.4% vs 0%), in olopatadine and vehicle groups, respectively."}